Zhaoke Ophthalmology Limited Announces Board Meeting to Approve 2025 Annual Results

Hong Kong, March 11, 2026 – Zhaoke Ophthalmology Limited (Stock Code: 6622), a leading player in the ophthalmology sector, has officially announced that its Board of Directors will convene a board meeting on Wednesday, March 25, 2026. The main agenda of this meeting is to consider and approve the annual results for the year ended December 31, 2025, covering both the Company and its subsidiaries.

Key Points Investors Need to Know

• Board Meeting Date: March 25, 2026.
• Purpose: Approval of the audited annual results for the financial year ended December 31, 2025.
• Scope: The results will cover both the parent company and its subsidiaries, providing a comprehensive view of group performance.
• Publication: The annual results will be published following the board meeting, allowing shareholders and the market to review the Company’s full-year financial performance.

Potential Market Impact and Price-Sensitive Information

This announcement is of significant importance to shareholders and market participants for several reasons:

• Financial Performance Disclosure: The annual results are a key indicator of the Company’s operational health, profitability, and future growth prospects. The outcome of this board meeting and the subsequent results release could directly influence the share price, depending on whether the results meet, exceed, or fall short of market expectations.
• Strategic Decisions: The board meeting may also include discussions on dividends, business strategies, or other material decisions that could impact shareholder value.
• Regulatory Compliance: Timely disclosure and approval of annual results are crucial for maintaining investor confidence and regulatory compliance on the Hong Kong Stock Exchange.

Board Composition

The current Board of Directors comprises the following members:

• Executive Directors: Dr. Li Xiaoyi (Chairman), Mr. Dai Xiangrong
• Non-Executive Directors: Ms. Leelalertsuphakun Wanee, Ms. Tiantian Zhang
• Independent Non-Executive Directors: Mr. Wong Hin Wing, Prof. Lo Yuk Lam, Mr. Liew Fui Kiang

What Should Shareholders Do?

Shareholders are advised to monitor the publication of the annual results closely, as the information disclosed could have material implications for the Company’s valuation and share price movement. Any significant changes in revenue, profit margins, or strategic direction announced in conjunction with the results may present investment opportunities or risks.

Disclaimer: This article is prepared for informational purposes only and does not constitute investment advice. Investors should exercise their own judgment and consult with professional advisors before making investment decisions. The information provided is based on company announcements and may be subject to change.

View ZHAOKE OPHTH-B Historical chart here